» Articles » PMID: 16433895

Positive Inotropic Effect of Levosimendan is Correlated to Its Stereoselective Ca2+-sensitizing Effect but Not to Stereoselective Phosphodiesterase Inhibition

Overview
Specialties Pharmacology
Toxicology
Date 2006 Jan 26
PMID 16433895
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In order to clarify the mechanisms of the positive inotropic actions of levosimendan and its optical isomer, dextrosimendan, we compared their concentration-dependent effects in intact papillary muscles, permeabilized cardiomyocytes and in purified phosphodiesterase enzyme preparations of guinea-pig hearts. In papillary muscles twitch tension increased with EC50 values of 60 nM and 2.8 microM for levosimendan and dextrosimendan, respectively. Hence, the two enantiomers exhibited a 47 times potency difference in their positive inotropic effects in a preparation where theoretically Ca2+-sensitization and phosphodiesterase inhibition could both contribute to the positive inotropic effects. In guinea-pig cardiomyocytes, levosimendan and dextrosimendan increased isometric force production (at pCa 6.2) due to Ca2+-sensitization with EC50 values of 8.4 nM and 0.64 microM, respectively, with a similar relative potency difference of 76. A major difference appeared in their relative pharmacological potencies, however, when the inhibitory effects of the two enantiomers were assayed on phosphodiesterase III, purified from guinea pig left ventricle (i.e. the phosphodiesterase isoenzyme which is dominant in that tissue). Levosimendan was a 427 times more potent phosphodiesterase inhibitor than dextrosimendan, with IC50 values of 7.5 nM, and 3.2 microM, respectively. Taken together, our data support the hypothesis that levosimendan and dextrosimendan exert their positive inotropic effects via a stereoselective Ca2+-sensitizing mechanism and not via stereoselective inhibition of phosphodiesterase III in the myocardium.

Citing Articles

Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium.

Rayo Abella L, Hoffmann R, Neumann J, Hofmann B, Gergs U Naunyn Schmiedebergs Arch Pharmacol. 2022; 396(4):669-682.

PMID: 36445386 PMC: 10042762. DOI: 10.1007/s00210-022-02348-7.


Thioimidate Bond Formation between Cardiac Troponin C and Nitrile-containing Compounds.

Klein B, Robertson I, Reiz B, Kampourakis T, Li L, Sykes B ACS Med Chem Lett. 2020; 10(6):1007-1012.

PMID: 32426091 PMC: 7227049. DOI: 10.1021/acsmedchemlett.9b00168.


Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.

de Waal L, Lewis T, Rees M, Tsherniak A, Wu X, Choi P Nat Chem Biol. 2015; 12(2):102-8.

PMID: 26656089 PMC: 4718766. DOI: 10.1038/nchembio.1984.


The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium.

Orstavik O, Manfra O, Andressen K, Andersen G, Skomedal T, Osnes J PLoS One. 2015; 10(3):e0115547.

PMID: 25738589 PMC: 4349697. DOI: 10.1371/journal.pone.0115547.


Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Orstavik O, Ata S, Riise J, Dahl C, Andersen G, Levy F Br J Pharmacol. 2014; 171(23):5169-81.

PMID: 24547784 PMC: 4294032. DOI: 10.1111/bph.12647.